Q-omics provides the consensus-scored TBX6 profile across patient tissues and cancer cell-line models. TBX6 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, TBX6 is differentially expressed in 13, with the highest sampling consensus in THCA. Additionally, TBX6 RNA expression shows 16,161 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight HNSC, THCA, and KIRP as cancer lineages where TBX6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TBX6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TBX6 survival associations across molecular data types. TBX6 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TBX6 RNA expression–survival associations across cancer types. High TBX6 expression shows unfavorable associations in COAD, but favorable associations in HNSC, STAD, LUSC, BRCA and ESCA. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for TBX6 RNA expression.
This table summarizes TBX6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for TBX6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TBX6 shows lower tumor expression in THCA and higher tumor expression in COAD, LIHC, LUAD, LUSC and KIRC. The THCA box plot shows higher TBX6 RNA expression in normal versus tumor tissue (log2 FC = −0.845, t-test p < 0.001).
This table shows molecular features associated with TBX6 in patient tissues and cancer cell lines. In patient samples, TBX6 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, TBX6 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and BONE.
